Background/Aims: The Barcelona Clinic Liver Cancer (BCLC) staging system is logical for the staging and treatment of hepatocellular carcinoma (HCC) because it was based on survival data. This study evaluated the applicability of the BCLC staging system and reasons for divergence from BCLC-recommended treatments in Korean HCC patients. Methods: One hundred and sixty consecutive HCC patients were prospectively enrolled. Treatments were generally recommended according to the guideline of the American Association for the Study of Liver Diseases, but patients were also informed about alternative treatments. The final decision was made with patient agreement, and was based on the doctor's preferences when a patient was unable to reach a decision. Results: There were 2 (1%), 101 (64%), 20 (12.5%), 34 (21.5%), and 3 (1%) patients with very early-, early-, intermediate-, advanced-, and terminal-stage disease, respectively. Only 64 patients (40%) were treated according to BCLC recommendations. The treatment deviated from BCLC recommendations in 68% (69/101) and 79% (27/34) of patients with early and advanced stage, respectively. The main causes of deviation were refusal to undergo surgery, the presence of an indeterminate malignancy nodule, the absence of a suitable donor, or financial problems. Conclusions: Donor shortage, financial problems, the relatively limited efficacy of molecular targeting agents, and the presence of an indeterminate nodule were the main causes of deviation from BCLC recommendations. Even after excluding cases in which decisions were made by patient preference, only 66% of the HCC patients were treated according to BCLC recommendations. Treatment guidelines that reflect the Korean situation are mandatory for HCC patients. (Korean J Hepatol 2011;17:113-119)
INTRODUCTION
(GRETCH) scoring system, 6 the Japanese Integrated Staging (JIS) score, 7 and Tokyo scoring system. 8 The BCLC staging system was proposed and has been validated by several groups in the United States and Europe to offer the best means of stage classification and treatment guidance for HCC. Accordingly, the BCLC staging system is viewed as being necessary for clinical trials and the reporting of clinical data. However, although this staging system was developed using an evidence-based approach, its application can be problematic because of differences between countries in terms of available medical resources, the lack of a broad consensus on its cost-effectiveness, the priority of surgical treatment, or because the tumor stage can be indeterminate as the BCLC system is based on clinical and radiological staging.
Therefore, the aims of this prospective study were to evaluate whether the BCLC staging system and its treatment guidelines are applicable in the majority of Korean HCC patients, and to identify causes of discrepancies. 
MATERIALS AND METHODS

Patients
Determination of treatment options
After determining BCLC stage, the hepatologist in charge, a surgeon, and radiologists discussed whether the treatment option recommended by the BCLC staging system was technically feasible. When the recommended treatment
could not be applied because of technical problems or the 
RESULTS
Patient characteristics
The baseline characteristics of the 160 patients are shown in Table 2 . Of these, 131 (82%) were men of mean age 56.7±
9.9 years. The etiologies of underlying liver disease were;
hepatitis B virus (77%), hepatitis C virus (9%), co-infection with hepatitis B and C virus (1%), and alcohol (6%). The numbers of patients in CTP classes A, B, and C were 137 (86%), 22 (13%), and 1 (1%), respectively. Table 3 ).
Classification of BCLC stage
The indeterminate lesions of the 18 patients of BCLC A were 12 dysplastic nodules in the liver, 2 arterio-portal (AP) (18) Intermediate ( In this prospective study, we undertook to determine the proportion of HCC patients that followed BCLC treatment guidelines.
Several factors affect the choice of treatment options. 
